True Leaf (MJ): A Multi-Pronged Approach to Capitalizing on Cannabis
August 24th, 2016
The North American cannabis industry is expected to grow at a nearly 30% pace to reach $20.7 billion in size by 2020, according to Research and Markets. While investors have many options to capitalize on this growth, few are as diversified as True Leaf Medicine International Ltd. (CSE: MJ) (FSE: TLA). The company targets U.S., Canadian and European markets with Hemp-based products for pets from its True Leaf Pet division and hopes to be supplying Canadians with Medical Marijuana from its True Leaf Medicine division upon Canadian government approval.
In this article, we will take a closer look at True Leaf Medicine International and why investors may want to consider it for their portfolios.
Near- & Long-term Plans
True Leaf Medicine International was founded in 2013 to become a licensed producer of medical marihuana under Canada’s MMPR program. The company was an early applicant in July, 2013 and has worked its way through to the ‘Security Clearance’ stage with Health Canada. With an ideal location supported by the community and a strong team in place, the company expects more progress with its application as the Canadian government transitions to a new program called the ‘ACMPR’ (Access to Cannabis for Medical Purposes Regulations) this August.
In the meantime, the company decided to forge ahead in a sector where its management team shared a common passion – pets. True Leaf Pet was formed to capitalize on growing demand for hemp and cannabinoid-based therapies for animals suffering from a range of conditions. The hemp-based nature of the company’s products means they aren’t subject to the same restrictions as marijuana and can be sold throughout the United States and Canada.
The company has already launched a line of functional hemp-based dog chews under the True Hemp™ brand names: CALMING, HIP + JOINT and HEALTH. According to a growing body of research, these products may help with anxiety and joint pain, as well as providing an antioxidant and cognitive boost. Apart from the hemp-derived components, these chews contain active ingredients like green lipped mussel, turmeric root, L-theanine, DHA from whole-cell algae, pomegranate extracts and more.
According to the American Pet Products Association, U.S. consumers spent over $60 billion on their pets last year alone. These figures include nearly $15 billion spent on pet supplies and over-the-counter medicine, which represents True Leaf Medicine’s core revenue opportunity.
The company remains in the very early stages of commercialization, but revenue continues to grow as more distribution is secured and their products reach pet stores. Through its network of distributors, the products are now available to over 9000 independent pet stores throughout North America. The company has also secured a European manufacturing partner and launched a European version of the same product line at the Interzoo® pet industry show in Nuremburg Germany last May. Distribution in that market is expected to commence in September 2016.
In early August, the company attended the SuperZoo trade show in Las Vegas, Nevada – one of the largest pet trade shows in the world – where it unveiled its new TrueHemp™ Sticks and TrueHemp™ Oil formats. Independent retailers attending the trade show responded enthusiastically to the new products since they provide an alternative delivery mechanism for older pets that may be pickier when it comes to accepting new formulations.
The company is focused on building its in-store and online presence across the United States, Canada, and Europe, as well as expanding its digital marketing efforts across North America over the coming quarters. In addition to these core markets, management has expressed an interest in expanding its presence into New Zealand, Australia, and parts of Asia where consumers may respond well to hemp-based therapies for pet ailments.
True Leaf Medicine International Ltd. (CSE: MJ) (FTA: TLA) represents a compelling opportunity within the burgeoning cannabis industry. With exposure to human and pet markets, the company aims to build a diversified company that’s unified by its goal to improve quality of life. The North American cannabis market is estimated to reach $20 billion in size by 2020, while consumers spend nearly $20 billion on pet supplies and over-the-counter medications.
For more information, visit the company’s website at www.trueleaf.com.
Follow Us on Social Media
Cannabis Financial Network (CannabisFN) is brought to you by TDM Financial, a financial media group and owner of SECFilings.com with over a decade of experience educating the markets, profiling public and private companies, and developing specific investor audiences. CannabisFN is the largest dedicated financial network covering the cannabis and medical marijuana (MMJ) industries and publishes industry news, thought leader and executive interviews, and stories on the fluid business and regulatory environment while serving as a leading corporate communications platform for companies operating in the industry.
Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.